[A14-11] Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)
Last updated 05.06.2014
Commission awarded on 11.03.2014 by the Federal Joint Committee (G-BA).
Skin and hair
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A14-15||Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)||Commission completed|
|A13-44||Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|